Author + information
- Received June 7, 2012
- Revision received August 24, 2012
- Accepted August 29, 2012
- Published online October 1, 2012.
- Joshua P. Loh, MBBS and
- Ron Waksman, MD⁎ ()
- ↵⁎Reprint requests and correspondence:
Dr. Ron Waksman, Washington Hospital Center, 110 Irving Street, North West, Suite 4B–1, Washington, DC 20010
The paclitaxel drug-coated balloon (DCB) is an emerging device in percutaneous coronary intervention, which has shown promising results by means of a high-concentration, rapid local release of an antirestenotic drug without the use of a durable polymer or metal scaffold. DCB have already proven effective in clinical trials for the treatment of in-stent restenosis. Its coronary applications may potentially be widened to a host of complex coronary de novo lesion subsets, such as small-caliber vessels, diabetes, and diffuse lesions, where the use of stents may be hampered by suboptimal results. Recently, this technology has rapidly evolved with newer studies added to assess the value of DCB in coronary applications other than in-stent restenosis. We present a review of the role of DCB in de novo coronary lesions based on this latest clinical evidence.
The authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received June 7, 2012.
- Revision received August 24, 2012.
- Accepted August 29, 2012.
- American College of Cardiology Foundation
- DCB Use in Small Vessel Disease
- DCB + BMS in De Novo Coronary Lesions
- DCB + BMS in Diabetes Mellitus
- DCB + BMS in CTO
- DCB + BMS in Acute Myocardial Infarction
- DCB-Only Approach in De Novo Coronary Lesions
- DCB-Only Approach In Diffuse Disease
- DCB in Bifurcation Lesions
- DCB + DES
- DAPT Requirements With DCB
- Conclusions and Future Perspectives